The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: Design, Methods, and Rationale
Open accessAbstract
The December 2003 report from the National Institute of Neurological Disorders and Stroke (NINDS) Workshop on priorities for clinical research in intracerebral hemorrhage (ICH) recommended clinical trials for evaluation of blood pressure management in acute ICH as a leading priority. The Special Writing Group of the Stroke Council of the American Heart Association in 1999 and 2007 emphasized the need for clinical trials to ensure evidence-based treatment of acute hypertensive response in ICH. To address important gaps in knowledge, we conducted a pilot study funded by the NINDS, Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) I Trial, during 2004–2008 to determine the appropriate level of systolic blood pressure (SBP) reduction. We now have initiated a multi-center, randomized Phase III trial, the ATACH II Trial, to definitively determine the efficacy of early, intensive, antihypertensive treatment using intravenous (IV) nicardipine initiated within 3 h of onset of ICH and continued for the next 24 h in subjects with spontaneous supratentorial ICH. The primary hypothesis of this large (N = 1,280), streamlined, and focused trial is that SBP reduction to ≤140 mm Hg reduces the likelihood of death or disability at 3 months after ICH, defined by modified Rankin scale score of 4–6, by at least 10% absolute compared to standard SBP reduction to ≤180 mm Hg. The ATACH II trial is a natural extension of numerous case series, the subsequent ATACH I pilot trial, and a preliminary, randomized, and controlled trial in this patient population funded by the Australian National Health and Medical Research Council. Both trials recently confirmed the safety and tolerability of both the regimen and goals of antihypertensive treatment in acutely hypertensive patients with ICH, as proposed in the present trial. The underlying mechanism for this expected beneficial effect of intensive treatment is presumably mediated through reduction of the rate and magnitude of hematoma expansion observed in approximately 73% of the patients with acute ICH. The Australian trial provided preliminary evidence of attenuation of hematoma expansion with intensive SBP reduction. The ATACH II trial will have important public health implications by providing evidence of, or lack thereof, regarding the efficacy and safety of acute antihypertensive treatment in subjects with ICH. This treatment represents a strategy that can be made widely available without the need for specialized equipment and personnel, and therefore, can make a major impact upon clinical practice for treating patients with ICH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Assessing proportionality in the proportional odds model for ordinal logistic regression.
Brant, R. (1990) · Biometrics · doi:10.2307/2532457 · Cited by 1,864
Spontaneous intracerebral hemorrhage
Qureshi, A. I., Tuhrim, S., Broderick, J. P., Batjer, H. H., Hondo, H., & Hanley, D. F. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441907 · Cited by 1,719
Self-citationEfficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707534 · Cited by 1,255
Clinical trials in head injury
Narayan, R. K., Michel, M. E., Ansell, B., Baethmann, A., Biegon, A., Bracken, M. B., Bullock, M. R., Choi, S. C., Clifton, G. L., Contant, C. F., et al. (2002) · Journal of Neurotrauma · doi:10.1089/089771502753754037 · Cited by 913 · cited 2×
“However, effect sizes of only 3–5% would translate into only 1,000–5,000 fewer deaths from TBI each year.”
Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events
Yusuf, S., Diener, H.-C., Sacco, R. L., Cotton, D., Ôunpuu, S., Lawton, W. A., Palesch, Y., Martin, R. H., Albers, G. W., Bath, P., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804593 · Cited by 785
Self-citation. Caution regarding the use of pilot studies to guide power calculations for study proposals.
Kraemer, H. C., Mintz, J., Noda, A., Tinklenberg, J., & Yesavage, J. A. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.5.484 · Cited by 702 · cited 1×
“Most pilot studies are small (fewer than 100 patients) and any differences in outcome must be dramatic to provide a trend [51, 52].”
Stratified Randomization for Clinical Trials
Kernan, W. N., Viscoli, C. M., Makuch, R. W., Brass, L. M., & Horwitz, R. I. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00138-3 · Cited by 627
Cited by
Hemphill, J. C., Greenberg, S. M., Anderson, C. S., Becker, K., Bendok, B. R., Cushman, M., Fung, G. L., Goldstein, J. N., Macdonald, R. L., Mitchell, P. H., et al. (2015) · Stroke · doi:10.1161/str.0000000000000069 · Cited by 3,994
Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage
Anderson, C. S., Heeley, E., Huang, Y., Wang, J., Stapf, C., Delcourt, C., Lindley, R., Robinson, T., Lavados, P., Neal, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214609 · Cited by 1,614
Morgenstern, L. B., Hemphill, J. C., Anderson, C., Becker, K., Broderick, J. P., Connolly, E. S., Greenberg, S. M., Huang, J. N., Macdonald, R. L., Messé, S. R., et al. (2010) · Stroke · doi:10.1161/str.0b013e3181ec611b · Cited by 1,496
Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage
Qureshi, A. I., Palesch, Y. Y., Barsan, W. G., Hanley, D. F., Hsu, C. Y., Martin, R. L., Moy, C. S., Silbergleit, R., Steiner, T., Suarez, J. I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603460 · Cited by 1,124
Self-citationHanley, D. F., Thompson, R. E., Rosenblum, M., Yenokyan, G., Lane, K., McBee, N., Mayo, S. W., Bistran-Hall, A. J., Gandhi, D., Mould, W. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30195-3 · Cited by 927
Metadata
- Authors
- Qureshi, A. I., & Palesch, Y. Y.
- Venue
- Neurocritical Care
- Published
- 2011-05-28
- Volume
- 15
- Issue
- 3
- Pages
- 559-576
- ISSN
- 1541-6933 (ISSN-L)
- 1556-0961
- OpenAlex
- W2008889136
- Cited by
- 229
- References
- 11
- FWCI
- 15.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: Design, Methods, and Rationale. https://app.cochat.ai/papers/10.1007/s12028-011-9538-3
- The paper
- Qureshi, A. I., & Palesch, Y. Y. (2011). Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: Design, Methods, and Rationale. Neurocritical Care. https://doi.org/10.1007/s12028-011-9538-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.